IPSEN (OTCMKTS:IPSEY – Get Free Report) has earned an average recommendation of “Hold” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company.
A number of brokerages have commented on IPSEY. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a research report on Sunday, August 2nd. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th.
Get Our Latest Stock Report on IPSEY
IPSEN Price Performance
Shares of IPSEY traded up $0.00 during trading hours on Tuesday, reaching $46.81. 4 shares of the company traded hands, compared to its average volume of 1,563. The business has a fifty day moving average price of $43.28 and a 200-day moving average price of $45.49. IPSEN has a 12-month low of $34.34 and a 12-month high of $51.10.
About IPSEN
IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.
Featured Stories
- Five stocks we like better than IPSEN
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
